Aspiryna u hospitalizowanych pacjentów z COVID-19: wyniki badania RECOVERY

RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021 online

Interpretation

In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.
Lancet, 17 listopada 2021
0 replies on “Aspiryna u hospitalizowanych pacjentów z COVID-19: wyniki badania RECOVERY”